Literature DB >> 25179174

Macrophages inhibit insulin signalling in adipocytes: role of inducible nitric oxide synthase and nitric oxide.

Alemu Fite1, Abdul Badi Abou-Samra2, Berhane Seyoum3.   

Abstract

OBJECTIVES: The interaction of immune cells with adipocytes within the adipose tissues in obese persons with diabetes mellitus may play a role in insulin resistance. We examined in vitro whether nitric oxide (NO) and inducible nitric oxide synthase (iNOS) play a role in impaired insulin signalling in adipocytes exposed to activated macrophages.
METHODS: We used a co-culture system in which Raw264.7 macrophages were plated over differentiated, low passage 3T3-L1 cells (dif3T3) at a cell density ratio of 1:2. Inflammation was induced by a challenge with bacterial lipopolysaccharide.
RESULTS: Significantly (p<0.001) enhanced iNOS expression and NO synthesis was observed in activated co-cultures. In the co-cultures as compared with Raw264.7 cells alone, iNOS protein was induced up to 11-fold above background, and NO release was significantly (p<0.001) increased up to 2.8-fold. Co-culturing dif3T3 and Raw264.7 cells as compared to dif3T3 alone reduced insulin-induced Akt phosphorylation by 50% and AS160 phosphorylation by 42%. This was correlated with reduced glucose consumption when dif3T3 was exposed to 1,3-morpholinosydnonimine. Adiponectin, GLUT4 and AS160 mRNA were reduced by 4-fold, 5-fold and 2-fold, respectively, in co-cultures as compared to dif3T3 alone. On the contrary, GLUT1 mRNA levels were increased by 2-fold in co-cultures as compared to dif3T3. NG-monomethyl-L-arginine abolished NO production with modest reversal of Akt/AS160 phosphorylation.
CONCLUSIONS: This study demonstrated a potential association between iNOS/NO-mediated inflammation and insulin resistance.
Copyright © 2015. Published by Elsevier Inc.

Entities:  

Keywords:  Akt et AS160; Akt/AS160; consommation de glucose; glucose consumption; infiltration macrophagique; inflammation; insulin resistance; insulinorésistance; macrophage infiltration

Mesh:

Substances:

Year:  2014        PMID: 25179174     DOI: 10.1016/j.jcjd.2014.02.023

Source DB:  PubMed          Journal:  Can J Diabetes        ISSN: 1499-2671            Impact factor:   4.190


  6 in total

1.  The suppressive effect of Gelidium amansi-EtOH extracts on the adipogenesis with MAPK signals in adipocytes with or without macrophages.

Authors:  Jeoungyeon Kim; Hack-Ju Kim; Myoungsook Lee
Journal:  Food Sci Biotechnol       Date:  2017-12-20       Impact factor: 2.391

2.  Inflamed macrophage microvesicles induce insulin resistance in human adipocytes.

Authors:  Yaqin Zhang; Li Shi; Hongliang Mei; Jiexin Zhang; Yunxia Zhu; Xiao Han; Dalong Zhu
Journal:  Nutr Metab (Lond)       Date:  2015-06-06       Impact factor: 4.169

3.  Targeting viperin improves diet-induced glucose intolerance but not adipose tissue inflammation.

Authors:  Zhengtang Qi; Jie Xia; Xiangli Xue; Jiatong Liu; Weina Liu; Shuzhe Ding
Journal:  Oncotarget       Date:  2017-09-08

4.  Blocking iNOS and endoplasmic reticulum stress synergistically improves insulin resistance in mice.

Authors:  Tamires M Zanotto; Paula G F Quaresma; Dioze Guadagnini; Lais Weissmann; Andressa C Santos; Juliana F Vecina; Kelly Calisto; Andrey Santos; Patrícia O Prada; Mario J A Saad
Journal:  Mol Metab       Date:  2016-12-19       Impact factor: 7.422

5.  No evidence for change in expression of TBC1D1 and TBC1D4 genes in cultured human adipocytes stimulated by myokines and adipokines.

Authors:  Łukasz Kępczyński; Szymon Wcisło; Irmina Korzeniewska-Dyl; Katarzyna Połatyńska; Agnieszka Gach; Dariusz Moczulski
Journal:  Adipocyte       Date:  2021-12       Impact factor: 4.534

6.  Methyl 3,4,5-trimethoxycinnamate suppresses inflammation in RAW264.7 macrophages and blocks macrophage-adipocyte interaction.

Authors:  Olumayokun A Olajide; Idowu S Akande; Carlos da Silva Maia Bezerra Filho; Izabela Lepiarz-Raba; Damião Pergentino de Sousa
Journal:  Inflammopharmacology       Date:  2020-05-16       Impact factor: 4.473

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.